Myriad Genetics Acquires Exclusive Rights to RAD51C Gene
Myriad Genetics, Inc. (Nasdaq: MYGN) today announced it has obtained an exclusive license to intellectual property covering the analysis of the RAD51C gene for risk of hereditary breast and ovarian cancer. In several studies, mutations in the RAD51C gene have been identified and associated with an increased risk for hereditary breast and ovarian cancer.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.